Home | Medinfo
Medical Response Documents, Slides, Meetings, Posters and Abstract
Disease State and Pipeline Information
Formulary Decision Resources and Real World Evidence

Medical Response Documents, Slides, Meetings, Posters and Abstract


Recent Searches

Login to access your saved recent searches.
Would you like to create your account? Save your information, bookmark your documents, and pick up where you left off when you switch devices...

Disease State and Pipeline Information

Global Pipeline





NSAINon-steroidal aromatase inhibitor

TafTafinlar® (dabrafenib)

MekMekinist® (trametinib)

aEU filing, approved in US.

bUS filing, approved in EU.

cUS filing, submitted in EU.

dUS pending submission, approved in EU.

eEU filing, submitted in US.


This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Login to access Dossiers / RWE search.
Would you like to create your account? Save your information, bookmark your documents, and pick up where you left off when you switch devices...
Report an Adverse Event

To report an adverse event,
please call 877-246-9236.

In case of medical emergency, please contact your healthcare provider immediately.

For any technical assistance or to provide feedback, please e-mail us at: emedinfo.support@novartis.com

Contact Us

Scientific Knowledge experts are available
M-F 8:30AM-5PM EST.

You can reach them by calling
888-NOW-NOVA (888-669-6682) to speak to a clinical expert regarding your question or to report a product quality complaint.

Contact Us

Live chat